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AbstrAct
Cachexia affects the majority of cancer patients, with currently no effective 
treatments. Cachexia is defined by increased fatigue and loss of muscle function 
resulting from muscle and fat depletion. Previous studies suggest that chemotherapy 
may contribute to cachexia, although the causes responsible for this association are 
not clear. The purpose of this study was to investigate the mechanism(s) associated 
with chemotherapy-related effects on body composition and muscle function. Normal 
mice were administered chemotherapy regimens used for the treatment of colorectal 
cancer, such as Folfox (5-FU, leucovorin, oxaliplatin) or Folfiri (5-FU, leucovorin, 
irinotecan) for 5 weeks. The animals that received chemotherapy exhibited concurrent 
loss of muscle mass and muscle weakness. Consistently with previous findings, muscle 
wasting was associated with up-regulation of ERK1/2 and p38 MAPKs. No changes 
in ubiquitin-dependent proteolysis or in the expression of TGFβ-family members 
were detected. Further, marked decreases in mitochondrial content, associated with 
abnormalities at the sarcomeric level and with increase in the number of glycolytic 
fibers were observed in the muscle of mice receiving chemotherapy. Finally, ACVR2B/
Fc or PD98059 prevented Folfiri-associated ERK1/2 activation and myofiber atrophy 
in C2C12 cultures. Our findings demonstrate that chemotherapy promotes MAPK-
dependent muscle atrophy as well as mitochondrial depletion and alterations of the 
sarcomeric units. Therefore, these findings suggest that chemotherapy potentially 
plays a causative role in the occurrence of muscle loss and weakness. Moreover, 
the present observations provide a strong rationale for testing ACVR2B/Fc or 
MEK1 inhibitors in combination with anticancer drugs as novel strategies aimed at 
preventing chemotherapy-associated muscle atrophy.
IntroductIon
Cachexia, a devastating condition occurring 
in 22% to 55% of advanced colorectal cancer cases, 
is associated with marked loss of body weight and 
depletion of fat and muscle storage [1, 2]. Cachexia 
is primarily characterized by skeletal muscle and 
adipose tissue wasting, but is also associated with 
increased fatigue, poor performance status, reduced 
quality of life and high mortality [3, 4]. Available 
evidence suggests that chemotherapy (i.e. the use of 
cytotoxic and antiproliferative drugs) may play a key 
role in the development and sustainment of cachexia. 
Chemotherapy is frequently accompanied by numerous 
side effects, including nausea, diarrhea, anorexia. 
Among these, increased muscle weakness represents one 
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of the most debilitating [5], affecting patient’s quality of 
life and resulting in increased morbidity and mortality. 
Despite the fact that the molecular mechanisms 
responsible for the development of cachexia have been 
studied for several decades, little is known about the 
effects of various cancer treatments on cachexia-related 
symptoms, and a plethora of conflicting observations 
are present in the literature. It has been suggested that 
several antineoplastic drugs may cause direct host cell 
modification as well as induce a negative nitrogen balance 
in healthy animals and in tumor hosts [6]. For instance, 
Damrauer et al. reported that several chemotherapeutics, 
including cisplatin, CPT-11, adriamycin, and etoposide, 
may directly cause muscle wasting via activation of the 
NF-κB pathway, and suggested that these effects were 
independent of their inhibition of tumor growth as well 
as commonly implicated ubiquitin-proteasome system 
or indirect effects via production of pro-inflammatory 
cytokines, such as IL-1β, IL-6 and TNF [7]. The same 
chemotherapeutics were also shown to induce oxidative 
stress, thereby promoting tissue injury [7–9]. In contrast 
with these observations, previous studies found that 
cisplatin, part of the standard care of treatment of 
lung, ovary, testicular and bladder cancers, activates 
inflammation and ubiquitin-dependent catabolism and 
down-regulates muscle anabolism in mice, thus leading 
to weight loss associated with loss of adipose tissue 
and muscle mass [10, 11]. Cisplatin was also show to 
up-regulate the expression of myostatin, a member of 
the TGF-beta family of growth factors also known to 
negatively regulate muscle mass in the occurrence of 
cancer, thus contributing to muscle wasting via activation 
of proteasome-dependent muscle catabolism [11–13]. 
Similarly, sorafenib, a multi-kinase inhibitor successfully 
tested for the treatment of several kinds of pre-clinical 
tumor models [14], was shown to promote muscle wasting 
in association with the activation of the ubiquitin-and 
Ca2+-dependent proteolytic systems [15]. 
Regardless of the mechanisms of action, preserving 
muscle mass may also represent an important therapeutic 
strategy for the treatment of cachexia associated with 
chemotherapy administration. Indeed, several indications 
recommended the use of strategies aimed at antagonizing 
myostatin in order to enhance muscle anabolism and 
prevent muscle catabolism in cancer cachexia and to 
prolong life, even in the absence of direct effects on 
tumor growth [13, 16–19]. Analogously, administration 
of ghrelin, an endogenous ligand for the growth hormone 
secretagogue receptor (GHSR)-1a, was shown to protect 
against cisplatin-induced cachexia by promoting muscle 
anabolism in experimental animals [11]. To further support 
the idea that promoting muscle mass may benefit patients’ 
tolerance to chemotherapy, it was also reported that cancer 
patients affected with muscle depletion (regardless of 
body weight) are more susceptible to developing severe 
drug-associated toxicity and show a poorer prognosis. In 
contrary, subjects with higher muscle mass or those who 
do not show sarcopenia at diagnosis are generally more 
resistant and may tolerate higher doses of chemotherapy 
that, in turn, would likely increase the chance of cure and 
disease-free survival [1, 20–23]. 
The purpose of this study was to investigate 
whether chemotherapeutics, such the ones that are 
utilized for the treatment of colorectal tumors, promote 
the development of cachexia. In order to do so, we 
tested in vivo chemotherapy regimens frequently used 
as preferred therapy for the treatment of colorectal 
cancers, in particular in the late metastatic stages of the 
disease, such as combinations of 5-fluorouracil (5-FU), 
leucovorin and either CPT-11 (i.e. Folfiri) or oxaliplatin 
(i.e. Folfox). We assessed muscle morphology and fiber 
size in the presence of anticancer compounds, effects on 
body composition and muscle strength, along with the 
modulation of chemotherapy-specific genes and proteins. 
We then investigated whether promoting muscle growth 
by using soluble Activin Receptor 2B (ACVR2B/Fc), a 
widely studied myostatin inhibitor, or whether preventing 
the activation of the MAPKs by administering PD98059, 
a MEK1 pharmacologic antagonist, in combination with 
Folfiri prevented the associated myofiber atrophy in 
C2C12 myotube cultures. The findings from this study 
suggest a potentially causative role for chemotherapy in 
the occurrence of muscle loss and weakness, and support 
the investigation of strategies making use of ACVR2B/Fc 
or MEK1 inhibitors in combination with anticancer drugs 
in order to prevent chemotherapy-associated cachexia.
results
In vivo chemotherapy administration causes 
adipose tissue and skeletal muscle weight loss as 
well as a transient decrease in food intake
In order to investigate whether chemotherapy 
was able to directly affect muscle mass growth 
and homeostasis, we administered Folfox or Folfiri 
chemotherapy regimens to adult (8-week old) male 
CD2F1 healthy mice (n = 8) for up to 5 weeks. Control 
animals were administered the vehicle only. We observed 
no changes in body weight over the first 3 weeks of 
treatment; however, the Folfiri-treated animals showed 
progressive body weight loss starting at week 4, while 
the mice receiving Folfox substantially maintained their 
initial body weight (Figure 1A). At the end of the 5-week 
period, the Folfiri-treated animals showed significant 
loss of body weight (about 10% vs. vehicle, p < 0.01; 
Figure 1A), consistent with marked loss of fat (Figure 1B) 
and lean tissue (Figure 1C). Notably, the administration 
of chemotherapy did not affect the overall body growth, 
as also supported by the absence of differences in the 
tibia length among Folfiri- and vehicle-treated animals 
(Figure S1). All the chemotherapy-treated animals showed 
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marked quadriceps muscle wasting (–23% vs. vehicle, 
p < 0.001), while only the mice that received Folfiri also 
exhibited loss of gastrocnemius and tibialis anterior mass 
(Figure 1D). Interestingly, the decrease in muscle mass 
following chemotherapy treatment was not associated 
with a reduction in the overall mobility, as shown by the 
mouse activity monitoring (Figure S2). Further, no effects 
on cardiac muscle were observed (Figure 1D). Following 
chemotherapy treatment, splenomegaly and severe 
depletion of gonadal adipose tissue and kidney mass were 
recorded (Figure 1E). In order to establish whether these 
effects were associated with changes in food intake, food 
consumption was monitored daily. Some sudden drops 
in food intake were detected in the mice soon after the 
administration of chemotherapy, although no significant 
difference in the average consumption was reported over 
the whole experimental period (Figure 1F; AUC Vehicle 
= 53.97, Folfox = 53.09, Folfiri = 51.26). Further, no 
significant alterations were observed in the morphology of 
the gastrointestinal tract from mice that were administered 
the chemotherapeutics (Figure 1G).
Folfiri-derived muscle atrophy associates with 
significant muscle weakness
Unlike Folfox, Folfiri caused marked depletion of 
skeletal muscle mass, consistent with reduction of fiber size 
in the tibialis anterior muscle (-20% vs. vehicle, p < 0.05; 
Figure 2A–2B). The loss of muscle mass experienced 
following Folfiri administration was also associated with 
a reduction in muscle strength, assessed as whole body 
muscle force (-17% vs. vehicle, p < 0.01; Figure 2C). 
However, the evaluation of the specific whole muscle 
strength (normalized to the body weight) did not show any 
Figure 1: In vivo chemotherapy administration causes adipose tissue and skeletal muscle weight loss. Body weights 
(A), body composition assessment (fat and lean tissues) performed by means of EchoMRI (b–c), muscle (d) and organ (e) weights in 
mice treated with chemotherapy for up to 5 weeks (n = 4–6). Weights were normalized to the Initial Body Weight (IBW) and expressed 
as weight/100mg IBW. Overall food intake over the 5-week experimental period (F). Representative gut morphology in vehicle- and 
chemotherapy-treated animals (G). FBW: Final Body Weight; GSN: Gastrocnemius; Gem: Gemcitabine. Significance of the differences: 
*p < 0.05; **p < 0.01; ***p < 0.001 vs. Vehicle.
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changes as compared to the control (Figure 2D). Notably, 
the ex-vivo muscle contractility assessment detected a 
marked decrease in EDL muscle force in the mice that 
were exposed to Folfiri for 5 weeks (Figure 2E–2F).
the muscle of mice exposed to chemotherapy 
exhibits up-regulation of ERK1/2 and p38 
MAPKs and down-regulation of mitochondrial 
proteins
In order to investigate whether the muscle phenotype 
observed following chemotherapy treatment was also 
associated with modulation of muscle-specific signaling 
pathways, we assessed the levels of a number of proteins 
known to be involved in the regulation of skeletal muscle 
growth. Interestingly, we observed modulation of several 
mediators of muscle atrophy or markers of mitochondrial 
biogenesis using Western blotting analysis performed 
on whole muscle protein extracts from mice exposed 
to chemotherapy, while contrary to previous reports in 
other experimental models [24, 25] muscle wasting did 
not seem to be associated with substantial modulation of 
autophagic degradation (Figure 3A–3B). In particular, all 
chemotherapy regimens showed hyperphosphorylation 
of both ERK1/2 and p38 MAPKs, thus suggesting that 
these signaling pathways might contribute to muscle 
Figure 2: Folfiri-derived muscle atrophy associates with significant muscle weakness. Muscle cross sectional area (CSA) in 
the tibialis muscle of mice exposed to chemotherapy (A) and tibialis anterior morphology (H&E staining) (b). Whole body grip strength, 
reported as peak force (c) and specific (normalized) force (d), was measured by taking advantage of a grip strength meter and expressed 
as the average of the three top pulls from each animal (n = 4–6). Ex-vivo muscle contractility was performed on EDL muscle excised from 
animals administered chemotherapy for up to 5 weeks (e–F). Data expressed as means ± SEM. Significance of the differences: *p < 0.05; 
**p < 0.01; ***p < 0.001 vs. Vehicle.
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wasting in the presence of anticancer treatments. These 
findings are consistent with previous data reported in 
other experimental conditions [26–28] (Figure 3A–3B). 
Of note, Folfiri administration was also associated with 
a significant reduction of muscle anabolism, as suggested 
by the decrease in AKT phosphorylation (Figure 3A– 3B). 
Interestingly, mitochondrial proteins, such as PGC- 1α, 
PGC-1β and Cytochrome C, were also markedly decreased 
in the muscle of the chemotherapy-treated mice, thereby 
suggesting that mitochondrial alterations might also 
contribute to the development of muscle wasting and 
increased muscle weakness. 
Chemotherapy-derived muscle wasting is 
not associated with activation of ubiquitin-
dependent proteolysis or on TGFβ expression
In order to test whether muscle wasting was 
associated with activation of muscle proteolysis, we 
measured the proteasome chymotrypsin activity in the 
quadriceps muscle of mice exposed to chemotherapy. No 
significant change was observed in the muscle of mice 
receiving either Folfox or Folfiri, unlike what shown in 
the quadriceps of mice bearing the C26 tumor (Figure 4A; 
see also [29, 30]). Further, gene expression analysis, 
performed by qRT-PCR, revealed no change in ubiquitin-
ligases commonly overexpressed in conditions of muscle 
wasting, such as Atrogin-1, MuRF-1, Fbxo21 (SMART), 
Fbxo30 (MUSA1) and Fbxo31 [24], as measured in the 
skeletal muscle of mice exposed to chemotherapy for 
up to 5 weeks (Figure 4B). Similarly, TGFβ-associated 
ligands, such as TGFβ-1 and -2, myostatin and Activin 
A, previously shown to play a causative role in conditions 
of muscle wasting [12, 31, 32], were unchanged in the 
muscle of animals treated with either Folfox or Folfiri 
(Figure 4C).  Interestingly, the expression of markers of 
myogenesis and pluripotency, such as MyoD, Myogenin 
and Pax-7, was unaffected by the treatment with 
chemotherapy (Figure 4D).
chemotherapy causes a shift towards more 
glycolitic fibers associated with marked 
depletion of mitochondria and aberrant muscle 
morphological features
In line with the marked reduction in mitochondrial 
proteins observed in Figure 3, the succinate dehydrogenase 
(SDH) activity in the muscle of mice exposed to Folfox 
or Folfiri was markedly reduced compared to the vehicle-
treated animals (Figure 5A–5B). This was also associated 
with a reduction in the size of both oxidative (dark blue) 
and glycolytic (light blue) fibers in the Folfiri treated 
animals (Figure 5C), in line with the CSA data displayed 
in Figure 2A–2B. Quite interestingly, chemotherapy was 
also shown to drive an oxidative to glycolytic fiber shift 
(Figure 5D), characterized by a reduction in oxidative 
fibers and a significant increase in the number of fibers 
associated with a more glycolytic metabolism in the 
tibialis muscle of mice exposed to either Folfox or Folfiri 
vs. Vehicle. Likewise, the TEM morphologic assessment 
of EDL muscles revealed major alterations at the 
sarcomeric level, with abnormalities consistent with fewer 
and smaller mitochondria (white arrows; Figure 6B– 6C) 
and with markedly thinner Z-lines (black arrows) in the 
mice that received any of the chemotherapy regimens 
(Figure 6A). Similarly, the I-band, mainly constituted 
of thin actin filaments, appeared thinner or completely 
absent, particularly in the Folfox-treated animals 
(brackets; Figure 6A). Consistent with the mitochondrial 
toxicity observed following chemotherapy administration, 
increased levels of ROS were detected in the muscle of 
mice exposed to either Folfox or Folfiri (Figure S3).
RNA-Seq analysis reveals down-regulation of 
mitochondrial metabolism and up-regulation of 
lipid transportation and energy metabolism
Gene expression profiling of quadriceps muscle, 
performed by means of RNA-Sequencing analysis, 
identified a limited set of genes that were significantly 
modulated (False Discovery Rate < 0.05) following Folfiri 
administration (Figure 7 and Table S1). Interestingly, 
the pathway analysis showed marked down-regulation 
of the regulators of mitochondrial metabolism Ucp1, 
Cidea1 and Acot2, as well as the marker of muscle cell 
proliferation/pluripotency Fhl3 (Figure 7 and Table S1). 
Further, we found increased expression of regulators of 
lipid metabolism and transport (such as Fabp1, Apoa1, 
Apob, Apoa2, Alb, Prkcz and Scd2) as well as acute 
phase response proteins (such as Alb, Fga and Fgb), and 
members of the PPAR signaling and markers of the Energy 
metabolism (such as Dnah5) were also detected (Figure 7 
and Table S1). 
ACVR2B/Fc or PD98059 counteract Folfiri-
mediated myofiber atrophy
In order to evaluate whether strategies aimed at 
improving muscle mass or preventing Folfiri-associated 
activation of the MAPK signaling also result into a 
substantial protection of muscle mass, we exposed C2C12 
murine myotubes to Folfiri, alone or in combination with 
either ACVR2B/Fc or PD98059, for 48h. Administration 
of ACVR2B/Fc (10 µg/ml) in the culture media was 
able to protect the myofibers from undergoing atrophy 
due to the Folfiri treatment (+31% vs. Folfiri, p < 0.05; 
Figure 8A–8B). In line with the observations reported 
in the in vivo model, Folfiri-dependent myotube atrophy 
(–13% vs. Control, p < 0.05) was associated with increased 
phosphorylation of the MAPK ERK1/2 and with reduced 
expression of the anabolic mediator AKT, already at a low 
dose (1:10) (Figure 8C–8D). Interestingly, the combined 
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administration of ACVR2B/Fc not only restored the 
AKT-dependent anabolism, as suggested by the levels of 
phospho-AKT, but also prevented the activation of MEK1 
and ERK1/2 (Figure 8C–8D). In order to investigate 
whether a more specific inhibition of ERK1/2 was able 
to prevent the Folfiri-dependent muscle protein loss, 
C2C12 myotubes were exposed to 20 μM MEK1 selective 
inhibitor PD98059 for up to 48h. Notably, the combined 
treatment showed a significant protection against Folfiri-
mediated myofiber atrophy (+33% vs. Folfiri, p < 0.05; 
Figure 8E–8F), consistently with an almost complete 
inhibition of ERK1/2 activation, as suggested by the levels 
of phospho ERK1/2 (Figure 8G–8H).
dIscussIon
The findings reported in the present study suggest 
that administration of antineoplastic drugs normally 
used for the therapy of colorectal cancer to healthy 
mice is associated with significant loss of muscle mass 
and reduced muscle strength, characterized by marked 
depletion in muscle mitochondrial content, reactive 
Figure 3: The muscle of mice exposed to chemotherapy exhibits up-regulation of ERK1/2 and p38 MAPKs and down-
regulation of mitochondrial proteins. Representative Western blotting (A) and quantification (b) for p-STAT3, STAT3, p-AKT, AKT, 
pMEK1/2, MEK1/2, p-ERK1/2, ERK1/2, p-p38, p38, PGC-1α, PGC-1β, Cytochrome C (Cyt-C), LC3B, Beclin-1 and p62 in muscle protein 
extracts from mice exposed to chemotherapy. Levels of phosphorylated proteins were normalized to the respective total protein expression. 
Tubulin was used as loading control. Data are expressed as Fold change vs. Vehicle and reported as means ± SEM. Significance of the 
differences: *p < 0.05; **p < 0.01; ***p < 0.001 vs. Vehicle. 
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oxygen species (ROS) release, oxidative to glycolytic 
muscle fiber shifts and change in the expression of 
known modulators of skeletal muscle wasting, such as 
the MAPKs ERK1/2 and p38. Importantly, we also show 
that administration of ACVR2B/Fc or MEK1 inhibitors 
prevents Folfiri-associated muscle atrophy in in vitro 
conditions, thus supporting the idea that promoting 
muscle anabolism or preventing MAPKs activation may 
potentially counteract chemotherapy-derived cachexia 
(Figure 9). 
Our observations are consistent with previously 
reported works, correlating the use of drugs with 
anti-proliferative activities with muscle atrophy and 
muscle weakness [6, 7]. It was previously proposed 
that chemotherapy may drive muscle atrophy due to 
the narrow therapeutic window of most antineoplastic 
agents, thereby leading to low efficacy in case of under-
dosing and, conversely, to severe side effects in case of 
over-dosing [1]. Additionally, most cytotoxic agents 
are associated with greater drug toxicity in patients that 
are muscle-depleted or have lower lean body mass, a 
compartment that contributes to metabolize most of the 
chemotherapeutics [1, 20, 21]. Notably, according to 
the current medical practice, individual chemotherapy 
dosage is based on the assessment of body surface 
area (BSA), although the validity of this practice is 
currently being questioned and few alternative strategies 
aimed at reducing drug-associated toxicity have been 
proposed [33, 34]. Accordingly, the amount of anticancer 
compounds tested in the present study was adapted from 
previously published reports, shown to safely inhibit 
tumor growth, and from our own preliminary dose curve 
Figure 4: Folfiri-mediated muscle wasting is not associated with ubiquitin-dependent proteolysis or with increased 
expression of TGFβ-associated ligands or markers of myogenesis. Chymotrypsin-like proteasome activity (U/ml) was performed 
on muscle from mice exposed to either Folfiri or Folfox and expressed as means ± SEM. Significance of the differences: *p < 0.05 
vs. Vehicle (A). Gene expression levels for Atrogin-1, MuRF-1, Fbxo21 (SMART), Fbxo30 (MUSA1), Fbxo31 (b), TGF-β1, TGF-β2, 
myostatin, Activin A (c), MyoD, Myogenin and Pax-7 (d) was performed by qRT-PCR (Light Cycler 96, Roche, Indianapolis, IN). Gene 
expression was normalized to TBP levels. Data (fold change vs. vehicle) expressed as means ± SEM. 
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Figure 5: Chemotherapy causes marked reduction in mitochondrial activity and increase in the number of glycolytic 
muscle fibers. Succinate dehydrogenase (SDH) staining was performed on 8 μm-thick sections from tibialis muscle frozen in liquid 
nitrogen-cooled isopentane (A). Quantification of signal intensity (expressed in pixels) (b), fiber-specific CSA (expressed as % of vehicle) 
(c) and number of oxidative (dark blue) and glycolytic (light blue) fibers (expressed as % of vehicle) (d) was assessed. Scale bar: 100 µm. 
Significance of the differences: *p < 0.05, **p < 0.01, ***p < 0.001 vs. Vehicle.
Figure 6: chemotherapy causes depletion of mitochondria and aberrant muscle morphological features. Electron microscopy 
micrographs (magnification: 30,000x) of EDL muscles from mice exposed to chemotherapy are reported in (A). White arrows indicate 
mitochondria. Black arrows indicate the Z-line. Brackets identify the I-bands. Scale bar: 500nm. Quantification of mitochondrial amount 
(number per field) (b) and size (minimum diameter, nm) (c) was performed. Significance of the differences: *p < 0.05, **p < 0.01 vs. Vehicle.
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experiments [35–37]. Moreover, aware of the limitations 
associated with directly comparing in vivo experimental 
protocols to chemotherapy regimens used in clinical 
practice, by taking advantage of the Meeh equation, used 
to assess BSA in mice, we made sure that the amount of 
drugs to be delivered to the experimental animals was 
not exceeding clinically relevant concentrations [38–42]. 
To further support the absence of severe toxicity in our 
model, we also showed that chemotherapy caused only 
transient reduction in food consumption in the animals 
administered chemotherapy, although the overall food 
intake in the animals receiving chemotherapy was similar 
in the mice treated with the vehicle alone. This observation 
is also consistent with the effects normally reported in 
oncologic patients undergoing chemotherapy treatment 
[43]. Interestingly, the skeletal muscle proteolytic systems, 
commonly implicated in conditions characterized by 
muscle atrophy [44], did not seem to be responsible for the 
muscle wasting caused by chemotherapy in this and our 
models, as also supported by the absence of modulation 
of proteasome activity and ubiquitin ligases expression. 
Similarly, the involvement of the autophagy-associated 
muscle degradation seemed to be minimal, unlike what 
reported in other models associated with muscle depletion 
due to cancer growth [25, 45], thus suggesting that other 
mechanisms may be responsible for muscle loss following 
chemotherapy administration in the absence of a tumor.
In this study, we found higher levels of MAPKs, 
such as ERK1/2 and p38, as well as decreased AKT-
dependent anabolism, particularly in association with 
Folfiri administration. MAPKs activation has been 
previously associated with muscle wasting [26, 46], 
and altered AKT-dependent anabolism and enhanced 
myostatin expression have both been implicated in 
cachexia [12, 13, 24, 47]. Of note, no p38 activation was 
reported in the muscle of Folfox-treated animals, unlike 
what we showed for the animals administered Folfiri. This 
might be explained by the difference in composition of 
the two chemotherapy regimens (e.g. CPT-11 in Folfiri vs. 
Oxaliplatin in Folfox) or by the dosing schedule utilized 
(e.g. animals were treated once a week with Folfox vs. 
twice a week with Folfiri). Nevertheless, absence of p38 
modulation was already reported in the muscle of C26-
bearing animals, whereas high levels of p-ERK1/2 were 
shown to be involved in regulating muscle loss in this 
experimental model [26]. Interestingly, evidence of a 
feedback loop between myostatin and MAPKs activation 
has been previously demonstrated and is supported by 
the finding that ACVR2B/Fc prevented the activation 
of both MEK1 and ERK1/2-dependent pathway in our 
model. Indeed, ERK1/2-mediated higher myostatin levels 
were reported in stress conditions, while myostatin was 
also shown to promote ERK1/2 activation, thus playing 
a role in repressing myoblast differentiation [48, 49]. In 
a previous study, wild type mice and mice bearing the 
Lewis Lung carcinoma showed hyperphosphorylation 
of p38 MAPK as well as inhibition of AKT signaling 
and activation of the myostatin pathway in response 
Figure 7: RNA-Seq analysis reveals down-regulation of mitochondrial metabolism and up-regulation of acute phase 
response proteins, lipid transportation and energy metabolism. Next-Generation RNA-sequencing was performed on whole 
RNA extracted from skeletal muscle of Vehicle- and Folfiri-treated animals (n = 4). RNA-Seq reads were mapped to the mouse genome 
(mm 9). Only statistically significant differentially expressed genes (False Discovery Rate < 5%) between Vehicle- and Folfiri-exposed 
muscles are reported in the figure.
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Figure 8: ACVR2B/Fc and PD98059 MEK1 inhibitor prevent Folfiri-associated muscle atrophy. C2C12 murine myotubes 
were exposed to Folfiri in combination with either ACVR2B/Fc (10 µg/ml) or PD98059 (20 μM) for 48 h and later stained for Myosin Heavy 
Chain (MHC), visualized as green (A) or red (e) staining. Quantification of fiber size (n = 500–600) is reported in (b–F). Representative 
Western blotting (c–G) and quantification (d–H) for pMEK1/2, MEK1/2, pERK1/2, ERK1/2, pAKT and AKT in total protein extracts 
from C2C12 cultures. Tubulin was used as loading control. Scale bar: 100 µm. Data expressed as means ± SEM. Significance of the 
differences: *p < 0.05; **p < 0.01. 
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to different chemotherapeutics [11, 50]. However, our 
findings did not show modulation in the expression of 
myostatin or any other TGFβ-family member following 
treatment with either Folfox or Folfiri, thus suggesting 
that, at least in the present experimental model, other 
mediators might drive chemotherapy-dependent muscle 
atrophy. 
The present study also found evidence of 
chemotherapy-related effects on sarcoplasmic and 
mitochondrial integrity. Ours is not the first evidence 
supporting the idea that mitochondrial alterations may 
contribute to drive muscle wasting in association with 
antineoplastic drugs. For example, previous studies 
showed that doxorubicin affects skeletal muscle mass and 
leads to loss of muscle tissue and increased fatigue and was 
also reported to augment the release of ROS by disrupting 
the mitochondrial energy metabolism [51]. This, in turn, is 
also known to promote the activation of MAPKs, such as 
ERK1/2 and p38, in the skeletal muscle [28]. In particular, 
our observations suggest that chemotherapy administration 
to normal animals significantly affects skeletal muscle 
mitochondrial content and is associated with increased 
release of ROS and with an increase in the number of 
glycolytic fibers. Similar skeletal muscle alterations, 
consistent with muscle weakness associated with 
mitochondrial ultrastructural abnormalities and reduced 
muscle oxidative capacity, are also reported in a setting 
of cancer cachexia [52]. Thus, these findings further 
support the idea that the concomitant use of antineoplastic 
drugs, by impinging on similar pro-atrophic mechanisms, 
might contribute to exacerbate cancer-associated muscle 
atrophy. Recently, it was also reported that pathologic 
TGFβ release in association with bone lesions mediates 
the occurrence of muscle weakness by causing alterations 
of Ca2+-dependent muscle force production in a metastatic 
breast cancer model [32]. However, at the time point 
that we analyzed we did not observe any change in the 
expression of TGFβ or any of the family members that we 
considered, at least in our experimental model. Ultimately, 
based on our findings, the occurrence of muscle weakness 
following chemotherapy administration may well result 
from a combined effect associated with the reduction 
of mitochondrial content and the loss of sarcoplasmic/
structural proteins, as also suggested by detecting thinner 
Z-lines and I-bands [51, 53]. 
These changes were also consistent with the 
observations reported by the RNA-Seq analysis, 
suggesting down-regulation of mitochondrial genes, 
and by the assessment of the levels of mitochondrial 
markers such as PGC-1α, PGC-1β and Cytochrome C 
[51, 53]. Interestingly, despite the depletion of muscle 
mitochondria, whose involvement in the β-oxidation 
process is known, our analysis also identified increased 
expression of genes associated with lipid metabolism, 
such as Fabp1, Apoa2, Apob, Apoh. Altogether, this could 
well represent a compensatory mechanism associated 
with the fact that the muscle fibers aim to restore energy 
homeostasis by importing more lipids that, however, due 
Figure 9: Representative model of chemotherapy-dependent cachexia. Based on our observations, chemotherapy causes 
mitochondrial depletion and (directly or indirectly) activation of ERK1/2 and p38 MAPKs-dependent pathways. Altogether, these 
alterations might lead to cachexia, characterized by loss of muscle mass and increased muscle weakness. Promoting muscle growth by 
taking advantage of ACVR2B/Fc or blocking ERK1/2 activation by means of the MEK1 pharmacologic inhibitor PD98059 can prevent 
muscle wasting. 
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to decreased mitochondrial capacity, cannot be broken 
down to acetyl-CoA and accumulate in muscle. This 
hypothesis is further supported by evidence showing that 
intramyocellular lipid droplets are detected in the presence 
of cancer and their number is proportional to weight loss 
and loss of adipose mass in other body compartments [54]. 
In our study, the peroxisome proliferator-activated 
receptor γ co-activator 1 (PGC-1) family of transcriptional 
co-activators have been known as central regulators of 
energy homeostasis in skeletal muscle and other tissues 
for quite some time. PGC-1α is a central mediator of 
muscle homeostasis and seems to be affected by almost 
all the signaling pathways that are activated in the 
contracting muscle fibers [55]. On the other hand, little 
is known about the role played by PGC-1β in skeletal 
muscle function, although it was reported to contribute to 
ameliorating lipid-induced insulin resistance and to reduce 
oxidative stress in skeletal muscle [56]. Interestingly, these 
sarcoplasmic and mitochondrial alterations mirror similar 
derangements observed in the muscle of tumor-bearing 
animals. These mice showing profound morphological 
changes at the sarcoplasmic levels were also shown to 
account for alterations resulting in energy insufficiency 
and significant muscle weakness associated with cancer 
cachexia [53, 57], thus further supporting the idea that 
similarities between chemotherapy-associated cachexia 
and tumor-derived cachexia exist. Indeed, based on 
the gene expression profiling, several genes encoding 
for acute phase response proteins, such as albumin and 
fibrinogens, are up-regulated in the muscle of Folfiri-
treated animals. Therefore, this evidence is consistent 
with our previous findings reported in the muscle of C26-
bearing animals, suggesting that skeletal muscle protein 
breakdown may contribute to the activation of a systemic 
acute phase response and to the sustainment of an overall 
inflammatory state [58]. 
Although the importance of the relationship between 
muscle mass vs. chemotherapy response/tolerability has 
been investigated for quite some time, no treatments 
have been approved thus far to minimize or prevent 
cancer therapy toxicities [1, 20, 21, 59]. Several pieces 
of evidence are available to suggest that counteracting 
muscle wasting by enhancing muscle anabolism or 
blocking muscle catabolism may not only improve quality 
of life and prolong survival in the presence of a tumor, but 
may also contribute to reduce chemotherapy toxicity, thus 
allowing to tolerate higher and more effective doses of drug 
[11, 18, 60]. In the present experimental work, although 
we were not able to detect any change in myostatin 
levels in the muscle of chemotherapy-treated animals, we 
tested the administration of ACVR2B/Fc, a well-known 
myostatin inhibitor, as a powerful tool aimed at mitigating 
chemotherapy toxicity in C2C12 cultures by promoting 
muscle anabolism per se. Notably, pharmacologically 
improving muscle mass by administration of ACVR2B/
Fc was also shown to rescue C26-associated cachexia and 
significantly prolong survival [12, 13, 18, 19]. Along the 
same line, the use of the anabolic agent ghrelin was shown 
to be partially successful in preventing cisplatin-associated 
muscle atrophy by reducing the inflammatory state and 
counteracting the activation of numerous pro-catabolic 
pathways [11, 61]. In a previous study, Fanzani et al. 
[62] showed that promoting muscle anabolism through 
insulin administration or delivery of a constitutively 
activated isoform of AKT counteracts chemotherapy-
induced protein breakdown and restores myofiber size. 
Analogously, supplementation with fish oil and selenium 
was reported to be beneficially effective in preventing 
inflammation- and myostatin-associated muscle atrophy 
in tumor-bearing mice undergoing anticancer therapy, 
thus suggesting that nutrition supplementation might be 
taken into consideration in association with chemotherapy 
[60]. Similarly, our observations show that PD98059 
selectively inhibits MEK1 and blocks activation of the 
downstream ERK1/2 pathways, thus also preventing 
muscle atrophy. Consistently, blockade of the ERK1/2-
dependent signaling mediated by MEK1 pharmacologic 
inhibitors was previously shown to promote anabolism 
and to protect muscle mass in cancer cachexia, as well 
as in patients affected with cholangiocarcinoma [26, 63]. 
In conclusion, muscle wasting and muscle weakness 
are not only debilitating and pervasive complications of 
cancer development that generally contribute to an overall 
worsening of the quality of life of cancer patients, but may 
also be ascribed to chemotherapy-associated side effects, 
resulting in diminished physical activity, reduced tolerance 
to anticancer therapies and overall increased morbidity 
[9]. Our study design, not resembling completely the 
clinical scenario, where only subjects affected with 
cancer typically receive chemotherapy, does not take 
into consideration the complexity of the interactions 
between tumor- and chemotherapy-driven mediators, thus 
limiting our findings to those signaling pathways that 
are activated exclusively in the presence of anticancer 
drugs. Moreover, the administration of chemotherapy to 
8-week old mice may seem to affect the normal tissue 
growth in animals that, although sexually mature, at 
this age have not reached full muscle development. 
Regardless, our observations prove that the chemotherapy 
treatment does not affect the overall body growth, as also 
supported by the analysis of the tibia length (comparable 
in both vehicle- and Folfiri-treated animals) and by the 
assessment of lean tissue mass (showing only a moderate, 
but not significant, growth in the vehicle-treated animals 
between day 0 and day 35). Nevertheless, our model 
system was able to isolate mediators of muscle wasting, 
as well as morphologic and functional alterations directly 
associated with the administration of antineoplastic 
drugs, therefore addressing a gap of knowledge that had 
not been investigated thus far. Importantly, our findings 
further support the idea that enhancing muscle mass and 
preventing chemotherapy-derived cachexia may represent 
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a novel strategy aimed to improve patients’ tolerance to 
anticancer drugs, thus also improving quality of life and 
increasing the chances for cure and tumor-free survival.
MAterIAls And MetHods
ethic statement
All animal experiments were conducted with 
the approval of the Institutional Animal Care and Use 
Committee at Indiana University School of Medicine 
and were in compliance with the National Institutes of 
Health Guidelines for Use and care of Laboratory Animals 
and with the ethical standards laid down in the 1964 
Declaration of Helsinki and its later amendments.
Animals
CD2F1 male mice (n = 8; Harlan, Indianapolis, 
IN) were administered intraperitoneally (i.p.) Folfiri 
(5-fluorouracil, leucovorin, CPT-11) or Folfox 
(5-fluorouracil, leucovorin, oxaliplatin) for up to 5 
consecutive weeks. All drugs were purchased from Sigma 
Aldrich (St. Louis, MO). The dosing schedule is shown 
in Table S2. Control mice received an equal volume of 
vehicle. The animals were weighed daily and their food 
consumption was recorded. At time of sacrifice, several 
tissues were collected, weighed, snap frozen in liquid 
nitrogen and stored at −80°C for further studies. The 
tibialis anterior muscle was frozen in liquid nitrogen-
cooled isopentane, mounted in OCT and stored for 
morphological analyses. 
cell culture
C2C12 skeletal myoblasts (ATCC, Manassas, VA) 
were grown in high glucose DMEM supplemented with 
10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 
100 mg/ml sodium pyruvate, 2 mM L-glutamine, and 
maintained at 37°C in 5% CO2. Differentiation to myotubes 
was induced by shifting confluent cultures to DMEM 
supplemented with 2% horse serum and replacing the 
medium every other day for 5 days. At 5 days, myotubes 
were exposed to different Folfiri (50 µg/ml 5-FU, 10 µg/ ml 
Leucovorin, 20 µg/ml CPT-11; Sigma Aldrich, St. Louis, 
MO), in combination with either PD98059 (20 µM; 
Selleckchem, Houston, TX) or ACVR2B/Fc (10 µg/ml) or 
for up to 48h. ACVR2B/Fc protein expression from the 
stable Chinese hamster ovary (CHO) cells was induced 
with 100 nM Cadmium in serum-free CHO media, and 
ACVR2B/Fc protein was purified from the conditioned 
medium using protein A Sepharose, as shown in [64]. 
CHO-ACVR2B/Fc cells were a kind gift of Dr. See-Jin 
Lee (Johns Hopkins University, Baltimore, MD).
Grip strength
The assessment of four-limb strength in 
experimental mice was performed by means of a 
commercially available automatic grip strength meter 
(Columbus Instruments, Columbus, OH) following the 
procedures described in [65]. Briefly, the absolute grip 
strength (expressed in grams) and the normalized grip 
strength (obtained by dividing the force value by the body 
weight of every single mouse) were recorded. In order to 
reduce procedure related variability, the same operator 
analyzed an average from several repeated peak force 
measurements in the same animal in a blind manner. For 
this assay, 5 measurements were performed, and the top 
three measurements were used for the analysis. Moreover, 
to avoid bias of habituation, the animals were tested once 
a week during the experimental period.
Ex-vivo muscle contractility
Whole muscle contractility of the extensor digitorum 
longus (EDL) muscles was determined as previously 
described [32, 65]. EDL were dissected from hind 
limbs; stainless steel hooks were tied to the tendons of 
the muscles using 4–0 silk sutures, and the muscles were 
mounted between a force transducer (Aurora Scientific, 
Aurora, ON, Canada) and an adjustable hook. The muscles 
were immersed in a stimulation chamber containing O2/
CO2 (95/5%) bubbled Tyrode solution (121 mM NaCl, 
5.0 mM KCl, 1.8 mM CaCl2, 0.5 mM MgCl2, 0.4 mM 
NaH2PO4, 24 mM NaHCO3, 0.1 mM EDTA, 5.5 mM 
glucose). The muscle was stimulated to contract using a 
supramaximal stimulus between two platinum electrodes. 
Data was collected via Dynamic Muscle Control/Data 
Acquisition (DMC) and Dynamic Muscle Control Data 
Analysis (DMA) programs (Aurora Scientific). At the 
start of each experiment the muscle length was adjusted 
to yield the maximum force. The force–frequency 
relationships were determined by triggering contraction 
using incremental stimulation frequencies (0.5ms pulses 
at 1–150 Hz for 350ms at supramaximal voltage). 
Between stimulations, the muscle was allowed to rest for 
3 min. At the end of the force measurement, the length 
(L0) and weight of the muscle was measured to facilitate 
determination of the specific force. Specific force is the 
absolute force normalized to the muscle the cross-sectional 
area, calculated as shown in [66]. The investigators were 
blinded to treatment of subjects. 
body composition assessment
Whole body composition (e.g. lean and fat tissue 
content) was measured every 7 days over the whole 
experimental periods in un-anesthetized but physically 
restrained mice using an Echo Medical systems’ 
EchoMRI-100 (EchoMRI, Houston, USA). Data were 
expressed as variations over the baseline values.
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Activity monitoring
Activity was assessed using non-invasive monitoring 
of horizontal and vertical movements by placing mice in 
Accuscan activity monitors. Briefly, mice were removed 
from their home cages and placed within the acrylic 
chambers of VersaMax AccuScan activity monitors. These 
activity monitors consist of four horizontal sensors and 
two vertical sensors, each containing 16 infrared beams set 
2.5 cm apart. Animal activity was detected and measured 
automatically by interruption of the infrared beams. 
Activity was recorded for 5 min and the movement was 
expressed as number of counts. Mice were then returned 
to their home cages. Based on our experience 5 min 
recording is sufficient to detect significant differences in 
horizontal or vertical movements. 
Real-time quantitative polymerase chain 
reaction (qRT-PCR)
RNA from quadriceps was isolated using the 
miRNeasy Mini kit (Qiagen, Valencia, CA, USA) and 
following the protocol provided by the manufacturer. RNA 
was quantified by using a Synergy H1 spectrophotometer 
(Biotek, Winooski, VT, USA). RNA integrity was checked 
by electrophoresis on 1.2% agarose gel containing 
0.02 mol/L morpholinopropanesulfonic acid and 18% 
formaldehyde. Total RNA was reverse transcribed to cDNA 
by using the Verso cDNA kit (Thermo Fisher Scientific, 
Waltham, MA, USA). Transcript levels were measured by 
Real-Time PCR (Light Cycler 96, Roche, Indianapolis, 
IN, USA) taking advantage of the TaqMan gene 
expression assay system (Life Technologies, Carlsbad, 
CA). In particular, expression levels for Atrogin-1 
(Mm00499523_m1), MuRF-1 (Mm01185221_ m1), 
Fbxo21 (SMART; Mm01208074_ m1), Fbxo30 (MUSA1; 
Mm01191299_ m1), Fbxo31 (Mm00505343_m1), TGF-β1 
(Mm1178820_m1), TGF-β2 (Mm00436955_ m1), 
myostatin (Mm01254559_m1), Activin A 
(Mm00434339_ m1), MyoD (Mm00440387_m1), 
Myogenin (Mm00446194_m1) and Pax-7 (Mm01354484_
m1) were detected. Gene expression was normalized 
to TBP (Mm01277042_m1) levels using the standard 
2-ΔCT methods. 
Western blotting
Total protein extracts were obtained by lysing 
cell layers or homogenizing 100 mg quadriceps muscle 
tissue in RIPA buffer (150 mM NaCl, 1.0% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, 
pH 8.0) completed with protease (Roche, Indianapolis, IN) 
and phosphatase (Thermo Scientific, Rockford, IL) 
inhibitor cocktails. Cell debris were removed by 
centrifugation (15 min, 14000 g) and the supernatant 
collected and stored at –80°C. Protein concentration 
was determined using the BCA protein assay method 
(Thermo Scientific, Rockford, IL). Protein extracts 
(30 µg) were then electrophoresed in 4–15% gradient 
SDS Criterion TGX precast gels (Bio- Rad, Hercules, 
CA). Gels were transferred to nitrocellulose membranes 
(Bio- Rad, Hercules, CA). Membranes were blocked 
with SEA BLOCK blocking reagent (Thermo Scientific, 
Rockford, IL) at room temperature for 1 hour, followed 
by an overnight incubation with diluted antibody in SEA 
BLOCK buffer containing 0.2% Tween-20 at 4°C with 
gentle shaking. After washing with PBS containing 0.2% 
Tween-20 (PBST), the membrane was incubated at room 
temperature for 1 hour with either Anti-rabbit IgG (H+L) 
DyLight 800 or Anti-mouse IgG (H+L) DyLight 600 
(Cell Signaling Technologies, Danvers, MA). Blots were 
then visualized with Odyssey Infrared Imaging System 
(LI-COR Biosciences, Lincoln, NE). Optical density 
measurements were taken using the Gel-Pro Analyzer 
software. Antibodies used were pSTAT3-Y705 (#9145), 
STAT3 (#8768), p-Akt-S473 (#4060), Akt (#9272), 
p-ERK1/2 (p-p44/42 MAPK, T202/Y204) (#4370), 
ERK1/2 (p44/42 MAPK) (#4695), pMEK1/2 (S217/221) 
(#9154), MEK1/2 (#9126), p-P38 MAPK (T180/Y182) 
(#4511), P38 MAPK (#9212), Cytochrome C (#11940) 
from Cell Signaling Technologies (Danvers, MA), 
PGC-1α (#ab3242), PGC-1β (#ab176328) from Abcam 
(Cambridge, MA), Beclin-1 (#B6186), LC3B (#L7543) 
from Sigma Aldrich (St. Louis, MO), p62 (#610832) 
from BD Biosciences (Franklin Lakes, NJ) and α-Tubulin 
(#12G10) from Developmental Studies Hybridoma Bank 
(Iowa City, IA).
Proteasome activity
Chymotrypsin-like proteasome activity in 
quadriceps muscle from mice treated with either Folfox 
or Folfiri was determined as shown in [67]. Briefly, the 
tissue was homogenized in 20 mM Tris–HCl, pH 7.2, 
containing 0.1 mM EDTA, 1 mM 2-mercaptoethanol, 
5 mM ATP, 20% glycerol, and 0.04% (v/v) Nonidet P-40. 
Muscle homogenates were then centrifuged at 13,000 × g 
for 15 minutes at 4°C. The supernatant was collected 
and protein concentration determined. Protein extracts 
were then incubated for up to 60 minutes at 37°C in the 
presence of 40 μM Suc-Leu-Leu-Val-Tyr-7-AMC specific 
fluorogenic substrate (Sigma Aldrich, St. Louis, MO), 
with or without MG-132 proteasome inhibitor (100 μM; 
EMD Millipore, Billerica, MA) in 50 mM Hepes, pH 8.0, 
5 mM EGTA buffer. Fluorescence was detected with a 
spectrofluorometer (350 nm excitation, 440 nm emission; 
Synergy H1, BioTek, Vinooski, VT). Proteasome extracts 
from quadriceps muscle excised from mice bearing the 
C26 tumor, known to activate proteasome-dependent 
muscle catabolism [68], were utilized as positive control. 
The activity, obtained by evaluating the release of free 
AMC, is expressed as units of proteasome activity per ml 
Oncotarget43456www.impactjournals.com/oncotarget
(U/ml), where one unit of proteasome activity is defined 
as the amount of proteasome which generates 1.0 nmol of 
AMC per minute at 37°C.
RNA-sequencing library construction and 
analysis
Standard methods were used for polyA mRNA-seq 
library construction, EZBead preparation and Next-Gen 
sequencing, based on Life Technologies SOLiD5000xl 
system. Briefly, one microgram total RNA per sample 
was applied for library preparation. PolyA mRNA was 
first captured using the standard protocol of Dynabeads® 
mRNA DIRECT™ Micro Kit (Life Technologies, 
#61021). Following the enrichment of polyA mRNA, 
the cDNA library was prepared and barcoded per sample 
using the standard protocol of SOLiD Total RNA-seq Kit 
(Life Technologies, #4445374). Each barcoded library 
was quantified by Bioanalyzer High Sensitivity DNA 
chip (Agilent, #5067-4626) and pooled in equal molarity. 
EZBead preparation, bead library amplification, and bead 
enrichment were then conducted using Life Technologies 
EZ Bead™ E80 System (Life Technologies, #4453095). 
Approximately four hundred forty million library-enriched 
beads per lane were deposited onto a SOLiD5500xl 
FlowChip (6 lanes/chip). Finally sequencing by ligation 
was carried out using standard single-read, 5′-3′ strand-
specific sequencing procedure (75b-read) on SOLiD5500xl 
Sequencer. The resulting 75 bp solid reads were mapped 
to Mus musculus mm9 reference genome using in-house 
mapping pipelines that utilizes bfast-0.7.0a [69]. In 
brief, using our RNA-seq pipeline, low quality reads and 
reads mapped to rRNA/tRNAs were first discarded. The 
remaining reads were mapped to reference genome mm9 
and a splice-junction library, respectively; the genomic 
and splice-junction library mapping were merged at the 
end. The gene based expression levels were calculated 
using bamutils from NGSUtils based on the RefSeq gene 
annotation of mm9 [70]. Differential expression of genes 
across different treatments was determined with edgeR 
[71]. Statistically significant differentially expressed genes 
(False Discovery Rate < 5%) between control and cachectic 
muscles were imported into Ingenuity Pathway Analysis 
(Qiagen, Valencia, CA) to identify significant pathways, 
upstream regulators, and causal networks. The data 
discussed in this publication have been deposited in NCBI’s 
Gene Expression Omnibus (GEO) [72]and are accessible 
through GEO Series accession number GSE80473.
ultrastructural analysis (transmission electron 
Microscopy - TEM)
EDL muscles were fixed with 3% Glutaraldehyde 
in 0.1 M sodium cacodylate (SC) buffer (pH 7.3) and, 
subsequently, rinsed three times in 0.1 M SC buffer. 
Muscle specimens were then post-fixed with 1% osmium 
tetroxide (OsO4) in 0.1 M SC buffer for 60 minutes. After 
post-fixation, samples were rinsed three times in 0.1 M SC 
buffer and dehydrated through a graded series of alcohol. 
The specimens were then placed in pure acetone for 
2 changes at 10 min each, followed by a 50:50 mixture of 
acetone and epoxy resin (Embed 812, EMS) for overnight 
on a rotating platform and finally into 100% epoxy resin 
for approximately 4 hours, under vacuum, then placed in 
fresh resin and polymerized overnight in a 60°C oven. 
Tissue blocks were sectioned at 80 nm on a Leica UCT 
ultramicrotome (Leica Biosystems, Inc., Buffalo Grove, 
IL) and picked up on copper grids. Sections were stained 
with a saturated solution of uranyl acetate in 50% Ethanol 
for 5 min and lead-citrate stained for 10–20 seconds. 
Grids were viewed using a FEI Tecnia G 12 Bio-Twin 
(Hillsboro, OR) and imaged with an AMT (Danvers, MA) 
CCD camera. Mitochondrial content was determined by 
quantifying the number and the size (minimum diameter) 
of each mitochondria per field. A total of 20 fields per 
condition were analyzed by taking advantage of the Image 
J software [73]. 
Morphological studies (fiber size, IF, SDH 
staining)
For histology and morphometry of muscle, tibialis 
anterior muscles were rapidly excised and mounted in OCT 
and frozen in liquid nitrogen-cooled isopentane for histology 
as shown in [57]. All samples were observed under an Axio 
Observer Z1 motorized microscope (Zeiss, Oberchoken, 
Germany) and calibrated images were recorded for 
morphometric examination. For skeletal muscle analyses, 
8 µm-thick cryosections of tibialis anterior muscles taken 
at the mid-belly were processed for Hematoxylin & Eosin 
or SDH (succinate dehydrogenase) staining. In particular, 
for the SDH staining sections were incubated for 30 min at 
37°C with 1 mg/mL NTB (nitrotetrazolium blue chloride) 
and 27 mg/mL Na- succinate in PBS. Afterwards the slides 
were washed three times in PBS, mounted with glycerol 
and photographed at different magnifications. Oxidative 
(dark blue) and glycolytic (light blue) fibers were quantified 
in tibialis anterior muscle sections stained for SDH and 
expressed as percentage of the total number of fibers per 
field. About 20 micrographs per condition were examined. 
For determination of the cross-sectional area (CSA), 
expressed as fiber area, muscle fibers (n = 300– 500 per 
sample) were measured by tracing the perimeter of each 
individual fiber using a Cintiq pen tablet input device 
(Wacom, Vancouver, WA, USA) and Image J 1.43 software 
[73]. For analysis of C2C12 myotube size, cells were 
fixed in ice-cold acetone-methanol and incubated with an 
anti-Myosin Heavy Chain antibody (1:1000, Millipore, 
Billerica, MA, USA) and an AlexaFluor 488- or AlexaFluor 
594-labeled secondary antibody (Invitrogen, Grand Island, 
NY, USA). Analysis of myotube size was performed by 
measuring the average diameter of long, multi-nucleate 
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fibers (n = 100–200 per condition) avoiding regions of 
clustered nuclei on a calibrated image using the Image J 
1.43 software [73].
Assessment of ROS levels
ROS were measured in cytosolic fractions 
using 2′, 7′-dichlorofluorescin diacetate (DCFH-DA) 
as a probe. DCFHDA is a stable, non-fluorescent 
molecule that readily crosses the cell membrane and is 
hydrolyzed by intracellular esterases to non-fluorescent 
2′, 7′-dichlorofluorescein (DCFH), which is rapidly 
oxidized, in the presence of peroxides, to highly 
fluorescent 2′, 7′-dichlorofluorescein (DCF). The DCF is 
then measured fluorimetrically, as shown in [74]. Results 
are expressed as units of fluorescence (UF)/µg protein.
statistical analysis
All results are expressed as means ± SEM. Western 
blots show independent samples and are representative 
of at least two trials. Significance of the differences was 
evaluated by unpaired T-test or analysis of variance 
(ANOVA) followed by Tukey’s post-test. Difference was 
considered significant when p < 0.05.
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